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Abstract
A COMPARISON OF MODERATE ORAL SEDATION DRUG REGIMENS FOR
PEDIATRIC DENTAL TREATMENT: A PILOT STUDY
By: Ojas A. Parikh, DDS
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
in Dentistry at Virginia Commonwealth University.
Virginia Commonwealth University, 2017
Thesis Advisor: William O. Dahlke, DMD
Assistant Program Director, Associate Professor, Department of Pediatric Dentistry
Purpose: Compare moderate oral sedation of pediatric patients using Hydroxyzine and
Meperidine with either Diazepam or Midazolam in management of pediatric dental patients.
Methods: Randomized, double-blind, crossover pilot study of patients 3 to 7 years of age
requiring two sedation visits. Frankl and Houpt behavior scores recorded at injection time,
initiation of treatment and 100% oxygen at end of treatment. Postoperative phone call surveys
conducted within eight hours and within 24 hours of discharge. Wilcoxon Signed-Rank tests,
Fisher’s Exact Chi-squared test and 0.10 significance level.
Results: 25 subjects completed 35 sedations. Eight participants completed both treatments and
demonstrated significantly higher total Houpt Scores with Diazepam at all treatment stages.
Frankl scores favored Diazepam at injection time. More abnormal behavior was found with
Midazolam, less memory of the visit with Diazepam, but longer sleep time with Diazepam.
Conclusions: Sedation with the Hydroxyzine, Meperidine and Diazepam regimen may allow for
a better overall sedation experience. Postoperative monitoring is essential. The results are
promising and demonstrate the value of a larger study on sedation with Diazepam.

Introduction
Treating pre-cooperative and anxious children in the dental chair is challenging, requiring
both skill and the appropriate tools for effective management.1,2 When chairside behavior
management techniques, which parents prefer, such as tell-show-do, voice control, nonverbal
communication, positive reinforcement, and distraction are not effective, oral sedation is an
effective option available to promote successful dental treatment.3

Oral sedation is most

accepted by pediatric patients, in comparison to intranasal, intravenous and intramuscular
sedation.4 Although mild, moderate and deep levels of sedation can all be induced by these
medications, our focus will be on the medications used to provide moderate level sedation.
According to the American Academy of Pediatric Dentistry (AAPD), moderate oral
sedation is the “drug-induced depression of consciousness” during which patients respond
purposefully to verbal commands.4 There is no intervention necessary to maintain an open
airway, and spontaneous ventilation is adequate while cardiovascular function is maintained.4,5
Patients medically qualified for moderate sedation must be relatively healthy with minimal
obstruction of the airway to minimize adverse events. This is classified by the American Society
of Anesthesiologists (ASA) as class I-II with a Brodsky tonsillar classification of 0-2. ASA I is a
normal healthy patient with no systemic disease and ASA II is a patient with mild to moderate
systemic disease that does not limit function2,6–15. Brodsky classification is the degree of tonsillar
blockage of the oropharynx with maximum acceptance in oral sedation of Brodsky II, which is
tonsillar blockage ranging from 25-50%.3,10,16,17 Advantages of oral sedation in particular include
reduced severity and incidence of adverse reactions, greater patient acceptance and compliance,
cost, and convenience of administration. 12 Limitations of oral sedation include an inability to
titrate the medications to desired effect given and its’ unpredictability due to variable absorption
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and first pass effects.8,13,18,19 The onset and recovery may also be prolonged and variable
because of individual variations in absorption which can delay patient discharge.18
Administration of moderate sedation requires a sedation license, specialized training and an
ability to rescue patients who have been sedated to a deeper level than intended.10 Most adverse
effects during pediatric dental anesthesia and sedation occurred when the sedation was done by
general dentists who had little to no advanced training in anesthesia, did not monitor the vital
signs of the patient during treatment and injected an excessive and toxic dose on local anesthetic
because they did not weigh the patient prior to treatment.7,20,21 Considering the potential
significant risks of sedation, the benefits outweigh those risks when patient selection is ideal and
sedation protocol is safely followed. According to the AAPD guidelines, vital signs (peripheral
capillary oxygen saturation with pulse oximetry, respiratory rate, heart rate (HR), blood pressure
(BP), and sometimes end-tidal CO2 with capnography) should be recorded at baseline, and every
five minutes after dosing the patient with the sedation medication until treatment is complete and
the patient is ready for discharge.
Oral sedation involves a wide spectrum of medications. Benzodiazepines such as
Midazolam and Diazepam, antihistamines such as Hydroxyzine, opioids such as Meperidine, and
Chloral Hydrate have been used individually or in combination for oral sedation in pediatric
dentistry for years.5 Nitrous oxide, an inhalation agent, is usually always used during oral
moderate sedation for pediatric dentistry patients. The triple regimen of oral moderate sedation
proves to be beneficial as the pharmacokinetics and pharmacodynamics help to minimize any
potential side effect an individual medication may have. For example, Meperidine used alone can
lower the seizure threshold and cause nausea and vomiting, however, when mixed with
Hydroxyzine, with its antiemetic and antihistamine properties, and a Benzodiazepine, with its
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anticonvulsant and amnesia properties, the side effects for Meperidine become minimal.
Combinations frequently used for oral sedation include the Midazolam, Hydroxyzine and
Meperidine combination as well as the Chloral Hydrate, Hydroxyzine and Meperidine
combination.22 Midazolam has been shown to be an effective tool for quick procedures due to its
fast onset time, but may induce restlessness, agitation, anxiety and sometimes aggressive
behavior. 23 Also, Chloral Hydrate lacks a reversal agent and as of May 2012, requires individual
prescriptions per patient so it is no longer preferred by pediatric dentists as a medication for use
in oral sedation.17,24 Therefore an alternative to Midazolam or Chloral hydrate may be indicated
in the sedation triple combination. Little research has compared the benzodiazepines,
Midazolam with Diazepam, in combination with Hydroxyzine and Meperidine. If Diazepam,
which is three to four times less potent than Midazolam, is substituted for Midazolam in such a
combination, how would behavior and recovery change in a pediatric dental patient? To
appreciate this, a better understanding of the individual medications is necessary.
Hydroxyzine is a medication with both antihistaminic and antiemetic effects. It causes
Central Nervous System (CNS) depression, anxiolysis, analgesia, sedation and
bronchodilation.7,25–27 It’s onset time is 15 to 30 minutes with 1.0 mg/kg orally, and it may
potentiate the effects of Meperidine as well as other CNS depressants.27 Meperidine is a narcotic
analgesic which causes CNS, cardiovascular, and respiratory depression, produces sedation,
analgesia, euphoria, and lowers the seizure threshold.2 Onset time is 30 minutes, peak effect is at
1 to 2 hours, dosage ranges from 1 to 2 mg/kg orally and maximum dosage is 50 mg.
Meperidine acts at the mu receptor, which functions as an inhibitory modulator of synaptic
transmission in the CNS. One undesirable effect is that Meperidine can lead to nonimmunologic histamine release. Therefore, combining it with Hydroxyzine will aid to counteract
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this histaminic effect. Benzodiazepines are sedative/hypnotic agents which cause CNS
depression and amnesia with minimal cardiovascular or respiratory effects.28,29 They act on the
limbic system, thalamus, and hypothalamus through mediation of the inhibitory neurotransmitter
GABA.30 Diazepam (Valium) has an onset time of 45 to 60 minutes and has a peak effect of 60
minutes.31 It has a dosage of 0.25 to 0.3 mg/kg orally, with a max dose of 10mg.32 However,
Diazepam has a long half-life because it has multiple active metabolites.12,30 Midazolam
(Versed) has an onset time of 15 minutes with a peak effect at 30 minutes and working time of
30 to 40 minutes.14 The dosage ranges from 0.5mg to 0.75mg, with a max dosage of 15mg.9 It
can be given via oral or intranasal administration and has fewer metabolites than Diazepam.
Nitrous oxide is a titratable inhalation sedative used often in conjunction with the
aforementioned medications to potentiate their effects and to assist in anxiolysis, sedation and
analgesia.10,13,17,19,22,33 The dosages of these medications are adjusted to minimize adverse effects
when combined for oral sedation.
Ultimately, the goal is to promote cooperative behavior in order to safely complete dental
treatment. Measuring behavior requires a standardized rating scale. The majority of oral
sedation studies utilize one or both of the Frankl Scale, which is a global scale, and the Houpt
Scale, which is a restricted scale.34 The Frankl Scale, seen in Appendix 1, is used to measure
overall behavior ranging from 1 to 4, with 1 being the worst behavior and 4 being the best
behavior. The Houpt Scale, seen in Appendix 2, is divided into various categories including
sleep, movement, and crying to allow for a more precise measurement in which lower scores
mean poor behavior and higher scores mean better behavior. Behavior studies have shown that
there is no correlation with poor behavior and previous dental treatment with oral sedation.33 Due
to sleepiness, drug-specific motor imbalance, and sleep during transit and recovery times greater
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than four hours, “vigilant adult supervision” is recommended post-discharge.20,35 Therefore,
measurement of post-discharge behavior is just as important as behavior during treatment.
The purpose of this study is to compare the effect of the moderate oral sedation triple
combination of Hydroxyzine and Meperidine with Diazepam or Midazolam in management of
pediatric dentistry patients.
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Materials and Methods

This study was a randomized double blind observational study of moderate oral sedation
treatment conducted at the Virginia Commonwealth University (VCU) School of Dentistry,
Department of Pediatric Dentistry. The protocol was approved by the VCU Institutional Review
Board, Committee on Human Research (VCU IRB# HM20006549) on June 16th, 2016.

Subject Selection Criteria
Following a power analysis for statistical significance, 25 participants between the ages
of 3 and 7 who were already treatment planned for oral moderate sedation from the VCU Dental
School, Department of Pediatric Dentistry were enrolled in the study for completion of two or
more quadrants of dentistry. Following the VCU School of Dentistry’s standard of care and
American Academy of Pediatric Dentistry (AAPD) guidelines, patient participants for oral
moderate sedation must have an ASA classification of I or II, present with history of fearful or
refractory behavior at previous dental visits documented by Frankl Scores of 1-3, and tonsillar
hypertrophy less than 50% characterized by Brodsky rating of 0 to 2. Patients are required to
obtain a history and physical examination by the primary care physician for clearance for oral
sedation. In addition, all participants are required to have fasted (NPO, nil per os, nothing by
mouth) midnight prior to the scheduled oral sedation visit. All consents and assents for the study
were signed by the guardians and participants the morning of the first oral sedation treatment.
Exclusion criteria for patients in this study include severe systemic disease, allergy to the
sedation and anesthetic medications used for treatment, nasal obstruction, recent upper
respiratory infections, limited neck movement, obesity, macroglossia, and tonsillar hypertrophy
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greater than 50%. According to the AAPD Sedation Guidelines, “children in ASA classes III
and IV, children with special needs, and those with anatomic airway abnormalities or extreme
tonsillar hypertrophy present issues that require additional and individual consideration and
therefore, practitioners are encouraged to consult with appropriate subspecialists.” Thus, those
patients were excluded from this study to avoid the risk of any complications.

Procedure
All participants were randomly assigned to be first treated with the Diazepam triple
regimen or the Midazolam triple regimen. The participants’ second visit was with the alternative
triple combination with identical dosage of Hydroxyzine, Meperidine and Nitrous Oxide as the
first visit to allow the individual to serve as his or her own control. The pediatric dentistry
resident and faculty attending were aware of the triple combinations given, however, the sedation
monitor, participant and parent were blind to the combination given for treatment. The reversal
agents for both combinations were the same, Flumazenil for the benzodiazepines (Diazepam and
Midazolam) and Naloxone for Meperidine. Calculations based on the child’s weight of
maximum local anesthetic delivery, oral sedation medication dosages and reversal agents were
done prior to delivery of medication.
The Diazepam triple regimen included Diazepam, Hydroxyzine and Meperidine, and the
Midazolam triple regimen included Midazolam, Hydroxyzine and Meperidine. Each of the
medications used were marketed and approved by the FDA for use orally, and for use in
combination with other medications. The medication dosages were tailored individually based
on the participant’s weight as follows:
Diazepam Triple Regimen
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1. Meperidine (Demerol)- narcotic/opioid, 1.0-2.0mg/kg, 50 mg max
2. Hydroxyzine HCl (Atarax)- antihistamine, 1.0-2.0mg/kg, 50 mg max
3. Diazepam (Valium)- benzodiazepine, 0.1-0.3mg/kg, 10 mg max
Midazolam Triple Regimen
1. Meperidine (Demerol)- narcotic/opioid, 1.0-2.0mg/kg, 50 mg max
2. Hydroxyzine HCl (Atarax)- antihistamine, 1.0-2.0mg/kg, 50 mg max
3. Midazolam (Versed)- benzodiazepine, 0.2-0.3mg/kg, 10 mg max

Vital signs (SpO2, respiratory rate, HR, BP and EtCO2) were recorded at the start of the
procedure and every five minutes afterwards until treatment was complete and the patient was
ready for discharge. Nitrous oxide was administered at concentrations ranging from 30 to 50%.
Behavior was evaluated by the monitor at injection time, start of procedure and when 100%
oxygen was administered at the completion of treatment using the Houpt Scale and Frankl Score.
The Houpt Scale comprises of scores in relation to sleep, movement, crying and overall
behavior.
Upon completion of treatment, a popsicle was given to ensure that the participant had
intact reflexes and was adequately hydrated. The patient was discharged when they met the
discharge criteria per AAPD Guidelines. These criteria include: airway patency is satisfactory
and stable, patient is easily arousable, responsiveness is at or near pre-sedation level, protective
reflexes are intact, patient can talk, patient can sit up unaided, and state of hydration is adequate.
Postoperative instructions were explained to the guardian and participant and the participant was
escorted via wheelchair to their car.
The guardian answered yes or no questions during postoperative phone calls made eight
hours and 24 hours after discharge regarding the participant’s behavior in the car ride home and
8

upon arrival home. Questions regarding sleep, memory, activity level, motor imbalance, nausea,
and emesis were asked. Those guardians who answered both sets of questions after both
sedation treatments were sent a check of $25.00 as a sign of appreciation for participation.
All pediatric dental residents and faculty involved were certified in Pediatric Advanced
Life Support (PALS) and Basic Life Support (BLS) training. Also, emergency management
training was conducted biannually. All personnel who participated as sedation monitors were
calibrated for Houpt and Frankl scoring prior to the study to ensure accuracy and consistency of
study measures.
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Results

Statistical Methods
Data was summarized using descriptive statistics. Differences among categorical
variables were compared using Fisher’s Exact Chi-squared test. Difference in behavior measures
and post-operative time spent sleeping were compared using Wilcoxon signed-rank tests. All
analyses were performed in SAS EG v.6.1 with a pilot study significance level of 0.10.
Results
A total of 25 subjects were enrolled in the study. A total of 35 sedation visits were
completed. Eight of the 25 patients successfully completed treatment under both sedation
methods. Of these eight, five had their initial sedation with Diazepam and the remaining three
started with Midazolam. A summary of the participation is given in Table 1. Demographics of all
participants and the subset with both visits are given in Table 2. There were no differences in
demographics between those who did and did not complete both sedations in terms of age,
gender, ethnicity, insurance type, locale, or treatment order.
Of the 35 attempted sedations, there were a total of eight failures. Three of the eight
occurred with the Diazepam and the remaining five were with Midazolam, resulting in failure
rates of 18% for Diazepam and 28% with Midazolam. However, this difference was not
statistically significant (p-value=0.6933). Additionally, two patients had to be excluded from the
second sedation because all treatment was completed during the first visit. Both of these cases
were completed with the Diazepam triple regimen. Seven patients failed to follow-up for the
second visit.
Behavior Scores
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Behavior scores were compared at injection time, treatment time, and 100% oxygen
administration at end of treatment for those who completed both treatments. A significance level
of 0.10 was used given the limited sample size and nature of the pilot study. Complete
breakdown of the scores are given in Table 2. Median scores were higher for Diazepam than
Midazolam for all measures, though not all differences were statistically significant. Frankl
scores were significantly different at injection time (p-value=0.0625). The median Frankl score
for Midazolam was 3 compared to 4 for Diazepam. Total Houpt scores were significantly
different at all treatment stages (injection, initiation of treatment, and 100% oxygen
administration at end of treatment). Median Houpt scores were higher for Diazepam than
Midazolam for all treatment stages (injection: 15.5 vs 13.5; initiation of treatment: 16 vs 13;
100% oxygen administration: 16 vs 14). Overall behavior scores were significantly different at
injection and initiation of treatment, but not at 100% oxygen administration at end of treatment.
At injection time, the median overall behavior score was 6 for Diazepam compared to 5 for
Midazolam (p-value=0.0625). At initiation of treatment, the median score was 6 for Diazepam
compared to 4.5 for Midazolam (p-value=0.0625). The higher the Frankl and Houpt behavior
scores, the more cooperative the study participant.
Side Effects
Parents were contacted within the first eight hours after discharge and questioned about
their child’s behavior. A summary of side effects reported are given in Table 3. Parents reported
more, though not statistically significant, abnormal behavior with Midazolam (43% vs 14%; pvalue=0.1573) and significantly less memory of the visit for Diazepam (43% vs 86%; pvalue=0.0833). Parents also reported longer sleeping times when returning home with Diazepam
than Midazolam (81.4 minutes vs 30 minutes), though this was not statistically significant (p-
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value=0.3125).
Parents and guardians were also contacted at 24-hours after discharge, but due to lack of
response from a majority of parents, there was insufficient data to analyze.
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Discussion
Oral moderate sedation is an essential tool when other behavior management techniques
are ineffective. The results from this study show that moderate sedation with the Diazepam
triple regimen containing both Hydroxyzine and Meperidine is more effective than the
Midazolam regimen during treatment, and resulted in less undesirable effects after treatment.
Previous studies have compared many different oral moderate sedation regimens for pediatric
dentistry, however no literature to date has been published comparing the combinations used in
this pilot study.
Studies have been conducted comparing the benzodiazepines Midazolam and Diazepam,
as single agents in the past. One found no statistical difference between the sedation effect of
oral Midazolam to oral Diazepam36 while another found that Midazolam was more effective in
regulating patient behavior at times of increased stimulation (papoose board, rubber dam,
injection time).37 One study also found that oral diazepam had no influence on behavior
management for dental treatment, which is contraindicatory to research claiming it does improve
behavior management.31 These contraindicatory findings indicate the need for further study.
Overall comparison suggests that the Diazepam regimen is the more favorable of the two.
Of the 25 participants who consented to the study, eight successfully completed treatment with
both regimens. Five of the eight had their initial sedation with Diazepam while three started with
Midazolam. A total of 35 sedations were completed, of which there were eight failures due to
uncooperative behavior. Three of those failures were with Diazepam (18%) while five were with
Midazolam (28%), this difference was not statistically significant (p-value=0.6933).
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Furthermore, two of the 25 participants had all of their treatment completed in the first treatment
with the Diazepam regimen because their behavior was so good it allowed for all treatment to be
completed. Therefore, this study revealed more failures with the Midazolam regimen and more
successful completions of treatment with the Diazepam regimen. This may have clinical
implications for pediatric dentists when selecting medication regimens for moderate sedation of
pediatric patients including more effective and predictable sedations, fewer failures, better
overall experience for the child, and better financial production for the dentist with the Diazepam
regimen.
Behavior was recorded at three treatment stages including injection time, initiation of
treatment, and at 100% oxygen administration at the end of treatment. Diazepam was favored
over Midazolam. Higher Frankl and Houpt scores generally indicate more favorable behavioral
outcomes. Frankl scores for injection time were statistically significant, favoring Diazepam (pvalue = 0.0625). Total Houpt scores were higher with Diazepam than Midazolam for all
treatment stages (injection: 15.5 vs 13.5; initiation of treatment: 16 vs 13; 100% oxygen
administration: 16 vs 14). The overall behavior scores were statistically significant at injection
time and initiation of treatment, favoring Diazepam. There was no statistical significance for
overall behavior during 100% administration and this may be due to lack of stimulation that
would likely elicit poor behavior. At injection time, the median Houpt score was six for
Diazepam and five for Midazolam (p-value=0.0625), while at initiation of treatment, the median
score was six for Diazepam compared to 4.5 for Midazolam (p-value=0.0625). These results
show that during treatment, the Diazepam regimen may be a better option during the treatment
stages resulting in less movement, less crying, and more somnolence. A very challenging part of
pediatric dental treatment is the delivery of local anesthetic, which can foreshadow the degree of
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patient cooperation for the remainder of treatment. In this study, the Frankl score was
significantly higher with the Diazepam triple during the injection procedure which is clinically
relevant for pediatric dentists, since majority of the failed sedations failed at injection time.
In addition to treatment outcomes, results also suggested a difference in post-discharge
side effects. Parents were contacted within eight hours of discharge, and answered post
discharge questions over the phone. Although not statistically significant, more abnormal
behavior was reported with Midazolam vs. Diazepam (43% vs. 14%) and less memory of the
visit was reported with Diazepam vs. Midazolam (43% vs 86%). A concern for Diazepam is the
longer half-life, which may have resulted in the longer sleep times noted upon arrival at home
with an average of 81.4 minutes with Diazepam vs. 30 minutes with Midazolam. However, this
result was not statistically significant (p-value of 0.3125). Though Diazepam seems to be the
better regimen during treatment, concerns over longer half-life are very important for post
discharge criteria, emphasizing the need for attentive supervision by parents in transportation to
and at the patient’s home. This is particularly important since Diazepam was used in
combination with two other medicaments, both of which can prove to have potentiating effects
and varying times of lasting effect.
Safety is the main priority when sedating young children and therefore, all treatment
providers were certified in Basic Life Support (BLS) and Pediatric Advanced Life Support
(PALS). Medication dosage calculations were specific to the participant’s weight and the
sedation protocol met the standards for both VCU Pediatric Dentistry and the AAPD guidelines.
A data safety and monitoring plan was implemented and any adverse event was recorded every
month, however all adverse events were mild involving routine repositioning of safety monitors
such as the pulse oximeter, for accurate readings. Most adverse effects during oral sedation,
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according to the literature, occur due to a lack of compliance with AAPD sedation monitoring
guidelines, and overdosing on local anesthetic.7 Our study did not result in any adverse effects
requiring medical attention or initiation of emergency protocol. There were instances where
treatment was aborted due to poor behavior which could have resulted in compromising the
safety of the study participant and of the study personnel. In such circumstances, patients were
worked up for treatment under general anesthesia. Adverse events including airway obstruction,
allergic reactions, bronchospasm, laryngospasm, respiratory depression, hypoxia and hypercarbia
did not occur in this study.
There are concerns surrounding the notion that a previous sedation visit could affect
patient behavior for future sedation treatments. A 2002 study in Pediatric Dentistry found no
correlation with poor behavior and previous dental treatment with oral sedation.33 Our study, in
particular, did not test this however it is something that we can focus on in future studies.
Despite numerous attempts to contact the participants, there was a high no-show and
cancellation rate. Of the 25 participants, seven failed to come for their second sedation visit.
Reasons for the high cancellation rate may include recent illness such as an upper respiratory
infection which elicits a four-to-six-week postponement per AAPD guidelines, scheduling
conflicts, an inability to communicate with parents due to altered contact information, or an
inability to meet parent’s expectations for the visit. For future studies, a better incentive plan can
be implemented which may help to retain more participants.
This pilot study had several limitations. The three to seven-year age range limited the
number of participants in the study, while the age range could have been divided into multiple
ranges from ages 1-6, 6-12 and greater than 12.32 The participant pool was primarily insured by
Medicaid and were of African American ethnicity from an urban locale, which is representative
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of our clinic population but not necessarily of a general population. The high sedation failure
rate may be because this study was conducted in a residency program where many of the patients
already have difficult behavior problems. In addition, ideally, the same resident or faculty
member would have monitored the Frankl and Houpt behavior scores to ensure consistency in
calibration, however, lack of personnel was a significant limitation. All residents are calibrated
for scoring upon entrance into the program, however no inter-rater agreement was done.
Postoperative surveys were challenging as the guardians often did not pick up the phone call, or
another relative or babysitter was monitoring the child at home while the guardian left for work
after discharge.
Future studies should incorporate a larger sample size of participants with a wider age
range comprising of an equal distribution of demographics and a larger number of personnel.
Better patient selection and more consistent behavior scoring methods may be indicated, possibly
with video recording of treatment to better rank behavior, or dual-monitoring with two providers
scoring patients and inter-rater testing. More focus on post discharge side effects may be of
greater significance as attentive adult supervision is essential after discharge especially with
Diazepam due to its longer half-life and Midazolam due to its effects on abnormal behavior and
difficulty of walking.20,35 Also, a future study comparing the two benzodiazepine combinations
with and without nitrous oxide may be of interest.
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Conclusion
Sedation with the Diazepam regimen may allow for a better experience for the pediatric
dental patient, the parent and doctor in comparison to the Midazolam regimen. The long half-life
of Diazepam is still a concern for sedation so proper monitoring by parents is essential during
travel to and at the patient’s home. Results from this study are promising and demonstrate value
of a larger study on treatment with the Diazepam regimen.
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Tables
Table 1: Study Participation
Study Participation
Enrolled
Failed First Visit
All Treatment Completed Visit 1
Completed Both Visits
Drop-outs

n (%)
25 (100%)
7 (28%)
2 (8%)
8 (32%)
8 (32%)

Table 2: Demographics

Demographics
Age (mean, SD)
Gender
Male
Female

Total
Sample
(n=25)
5.4 (1.41)

Completed
Study (n=8)
5.5 (1.31)

15 (60%)
10 (40%)

5 (63%)
3 (38%)

Race/Ethnicity
African American
14 (56%)
3 (38%)
Asian American
1 (4%)
1 (13%)
Caucasian
7 (28%)
4 (50%)
Hispanic
2 (8%)
0 (0%)
Middle Eastern
1 (4%)
0 (0%)
Insurance Type
Medicaid
19 (76%)
7 (88%)
Private Insurance
6 (24%)
1 (13%)
Locale
Urban
20 (80%)
7 (88%)
Rural
5 (20%)
1 (13%)
Treatment Order
Midazolam-Diazepam
12 (48%)
3 (38%)
Diazepam-Midazolam
13 (52%)
5 (63%)
*p-value from t-test or chi-squared test, as appropriate
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P-value*
0.8142
1.0000

0.1674

0.6237

1.0000

0.6728

Table 3: Median Behavior Scores by Treatment
Median
Midazola
Diazepa
m
m

P-value*

Frankl
Injection
3
4
Treatment
3
4
Oxygen
3.5
4
Houpt
Houpt: Sleep
Injection
2
2
Treatment
2
2
Oxygen
2
2
Houpt:
Movement
Injection
3
4
Treatment
3
4
Oxygen
3.5
4
Houpt: Crying
Injection
3
4
Treatment
3.5
4
Oxygen
4
4
Houpt: Total
Injection
13.5
15.5
Treatment
13
16
Oxygen
14
16
Overall
Injection
5
6
Treatment
4.5
6
Oxygen
5
6
*P-value from Wilcoxon Signed-Rank Test
†Indicates significant difference at 0.10 level
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0.0625 †
0.2500
0.2500

0.6250
0.5000
0.3750

0.2188
0.3125
0.5000
0.5000
0.2500
0.5000
0.0625 †
0.0781 †
0.0313 †
0.0625 †
0.0625 †
0.1250

Table 4: Post-Op Phone Call Survey
Midazolam
3 (43%)
1 (14%)
1 (14%)
0 (0%)
6 (86%)
2 (29%)
Midazolam
30 (45.83)

Abnormal Behavior
Difficulty Walking
Dizziness
Nausea
Remember Visit
Play at Home
Time Slept (Mean, SD)
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Diazepam
1 (14%)
0 (0%)
1 (14%)
1 (14%)
3 (43%)
0 (0%)
Diazepam
81.4 (80.71)

Figures

Figure 1: Frankl Scores at Various Treatment Stages

†Indicates significant difference at 0.10 level

Figure 2: Median Houpt Scores at Various Stages by Sedation Medication
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Figure 3: Median Total Houpt Scores by Treatment Stage and Medication

†Indicates significant difference at 0.10 level

Figure 4: Median Overall Behavior Scores by Treatment Stage and Medication

†Indicates significant difference at 0.10
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Appendix 1: Frankl Behavior Scale

Rating

Description

1 (--) Definitely Negative

Refuses treatment,
cries forcefully,
extremely negative
behavior associated
with fear

3 (+) Positive

Reluctant to accept
treatment and
displays evidence of
slight negativism
Accept treatment, but
if the child has a bad
experience during
treatment, may
become
uncooperative

4 (++) Definitely Positive

Unique behavior,
looks forward to and
understands the
importance of good
preventive care.

2 (-) Negative
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Appendix 2: Houpt Behavior Scale

Houpt Scale
Rating for sleep

Description

1 Fully awake, alert
2 Drowsy, disoriented
3 Asleep
Rating for movement
1 Violent movement interrupting treatment
2 Continuous movement making treatment difficult
3 Controllable movement that does not interfere with treatment
4 No movement
Rating for crying
1 Hysterical crying that demands attention
2 Continuous, persistent crying that makes treatment difficult
3 Intermittent, mild crying that does not interfere with treatment
4 No crying
Rating for overall behavior
1 Aborted- no treatment rendered
2 Poor- treatment interrupted, only partial treatment completed
3 Fair- treatment interrupted, but eventually all completed
4 Good-difficult, but all treatment performed
5 Very good- some limited crying or movement, e.g., during anesthesia or mouth prop in
6 Excellent- no crying or movement
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Appendix 3: Behavior Scale Rating Sheet

Procedure
Injection Time

Initiation of
Treatment

100% Oxygen
via nasal hood
post-treatment

Frankl Score

Behavior Category
Sleep
Movement
Crying
Overall Behavior
Total
Sleep
Movement
Crying
Overall Behavior
Total

Sleep
Movement
Crying
Overall Behavior
Total
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Houpt Rating

Appendix 4: Post-Op Phone Call Survey

Post Op Phone Call
Questions:
Did your child:

Yes

No

1. Exhibit any abnormal
behavior?
2. Fall asleep on the car ride
home?
Does your child normally
sleep in car?
Did your child snore?
Does your child usually
snore?
Was it difficult to awaken
your child when you arrived
home?
3. Sleep soon after arriving
home?
4. Did your child snore?
Does your child usually
snore?
5. Have difficulty walking?
6. Complain of or seem
dizzy?
7. Play immediately after
arriving home?
8. Have any memory of what
happened at the dental
office?
9. Complain of nausea?
10. Vomit?
Did your child consume any
liquids or foods before
vomiting?
11. Have an upset stomach?
How long did they sleep after
arriving home?

# minutes
________
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Appendix 5: Sedation Medications Used

Medication
Diazepam oral solution
Diazepam tablet
Meperidine oral solution
Midazolam syrup
Hydroxyzine tablet
Hydroxyzine syrup
Nitrous oxide

Concentration
5mg/ml
5mg
50mg/5ml
2mg/ml
25mg
10mg/5ml

Manufacturer
Roxane Laboratories
Mylan Inst.
Roxane Laboratories
Roxane Laboratories
Pfizer
Silarx Pharmaceuticals, Inc.
Airgas USA, LLC (Puritan Medical)
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